Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S. provisional patent application seeking to protect a new TeloView® biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease ("MRD") in the management of patients with multiple myeloma ("MM").
"This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView® platform," said John Farlinger, Telo's CEO. "As MRD becomes increasingly important in multiple myeloma patient assessment and treatment development, we believe there is a significant opportunity to advance blood-based approaches that complement the current clinical practice."
The latest patent application aims to protect a new TeloView® algorithm that can predict the risk of relapses in MM patients and the workflow to isolate circulating cancer cells from peripheral blood samples in the MRD setting. This expanded IP portfolio will strengthen Telo's competitive position, support future commercial partnerships, and further differentiate TeloView® from existing MRD technologies.
TeloView® is a proprietary diagnostic platform which analyzes the three-dimensional (3D) telomere and nuclear architecture to assess genomic instability, a fundamental driver of cancer progression. This technology works even at the level of single cell analysis. The platform has generated multiple prognostic algorithms applicable in oncology and neurodegenerative diseases. Telo continues to expand its intellectual property portfolio to protect these clinical applications, with patent coverage for TeloView® extending through 2043.
MRD is an FDA-approved clinical endpoint, and MRD assessment has become an increasingly important component of MM clinical practice, research, and drug development. However, currently available MRD technologies primarily measure residual tumor burden and generally require invasive bone marrow samples, limiting their suitability for routine longitudinal monitoring of patients and providing limited insight into the biological status of that residual disease. Telo's peripheral blood MRD development program aims to validate a non-invasive clinical assay that can regularly measure the presence or absence of MRD and additionally provide a measure of the risk of relapse to guide the use of therapeutics. Telo expects such an assay to lower healthcare costs and improve patient care outcomes. One of the ongoing studies to validate this clinical test is based on a collaboration with the University of Athens who has provided a large cohort of liquid biopsy samples for MRD testing where there are commensurate EuroFlow results to compare.